BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 163.97% ano a ano.
Virada para Lucro
O desempenho da empresa passou a ser positivo, com lucro líquido anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é -5.81, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 235.68M ações, um aumento de 2.71% em relação ao trimestre anterior.